APRE
insider transactionsAprea Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 3 different insiders made open-market purchases in the last 365 days, totalling $155.1K.
Net shares · 365d
+377.4K
377.4K buy · 0 sell
Net value · 365d
$155.1K
$155.1K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
8
377.4K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +109%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +300%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +101%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +31%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +300%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +1%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +58%
-
Grant·A
Director
$0
12.6K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +7%
-
Buy·P
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
—
31.0K sh
Own New
-
Buy·P
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
$25.0K
31.0K sh · $0.81
Own New
-
Buy·P
Director
—
123.9K sh
Own New
-
Buy·P
Director
$100.0K
123.9K sh · $0.81
Own New
-
Grant·A
Oren Gilad KEY
President/CEO
$0
80.7K sh
Own New
-
Grant·A
Oren Gilad KEY
President/CEO
$0
20.2K sh
Own +5%
-
Grant·A
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
$0
40.4K sh
Own New
-
Grant·A
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
$0
10.1K sh
Own +30%
-
Buy·P
Oren Gilad KEY
President/CEO
—
28.1K sh
Own New
-
Buy·P
Oren Gilad KEY
President/CEO
$25.0K
28.1K sh · $0.89
Own +8%
-
Buy·P
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
—
5.7K sh
Own New
-
Buy·P
John P. Hamill KEY
SrVP/CFO/Prin Fin & Acct Ofcr
$5.1K
5.7K sh · $0.89
Own +21%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Michael Grissinger | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Michael Grissinger | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Gabriela Gruia | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Gabriela Gruia | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Richard Peters | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Richard Peters | Grant A | 3.1K | $0 |
| Jun 16, 2026 | John B Henneman III | Grant A | 12.6K | $0 |
| Jun 16, 2026 | John B Henneman III | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Jean-Pierre Bizzari | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Jean-Pierre Bizzari | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Marc Duey | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Marc Duey | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Rifat Pamukcu | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Rifat Pamukcu | Grant A | 3.1K | $0 |
| Jun 16, 2026 | Bernd R. Seizinger | Grant A | 12.6K | $0 |
| Jun 16, 2026 | Bernd R. Seizinger | Grant A | 3.1K | $0 |
| Mar 31, 2026 | John P. Hamill KEY | Buy P | 31.0K | — |
| Mar 31, 2026 | John P. Hamill KEY | Buy P | 31.0K | $25.0K |
| Mar 31, 2026 | Richard Peters | Buy P | 123.9K | — |
| Mar 31, 2026 | Richard Peters | Buy P | 123.9K | $100.0K |
| Mar 12, 2026 | Oren Gilad KEY | Grant A | 80.7K | $0 |
| Mar 12, 2026 | Oren Gilad KEY | Grant A | 20.2K | $0 |
| Mar 12, 2026 | John P. Hamill KEY | Grant A | 40.4K | $0 |
| Mar 12, 2026 | John P. Hamill KEY | Grant A | 10.1K | $0 |
| Jan 30, 2026 | Oren Gilad KEY | Buy P | 28.1K | — |
| Jan 30, 2026 | Oren Gilad KEY | Buy P | 28.1K | $25.0K |
| Jan 30, 2026 | John P. Hamill KEY | Buy P | 5.7K | — |
| Jan 30, 2026 | John P. Hamill KEY | Buy P | 5.7K | $5.1K |
About APRE insider trading
This page tracks insider transactions for Aprea Therapeutics, Inc. (APRE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.